Table 2 Baseline features of p53 status in the training and validation cohorts
Characteristics | Training cohort (n = 210) | Validation cohort (n = 90) | |||||
|---|---|---|---|---|---|---|---|
p53 WT (n = 90) | p53 Mut (n = 120) | P- value | p53 WT (n = 44) | p53 Mut (n = 46) | P- value | ||
Gender (n, %) | Male | 57 (63.33) | 91 (75.83) | 0.066 | 33 (75.00) | 31 (67.39) | 0.426 |
Female | 33 (36.67) | 29 (24.17) | 11 (25.00) | 15 (32.61) | |||
CRM status (n, %) | Negative | 70 (77.78) | 91 (75.83) | 0.742 | 30 (68.18) | 37 (80.43) | 0.183 |
Positive | 20 (22.22) | 29 (24.17) | 14 (31.82) | 9 (19.57) | |||
Mri-EMVI status (n, %) | Negative | 71 (78.89) | 90 (75.00) | 0.51 | 33 (75.00) | 31 (67.39) | 0.426 |
Positive | 19 (21.11) | 30 (25.00) | 11 (25.00) | 15 (32.61) | |||
ACI status (n, %) | Negative | 86 (95.56) | 115 (95.83) | 0.806 | 38 (86.36) | 45 (97.83) | 0.102 |
Positive | 4 (4.44) | 5 (4.17) | 6 (13.64) | 1 (2.17) | |||
Lymph Node (n, %) | No met | 38 (42.22) | 40 (33.33) | 0.187 | 16 (36.36) | 17 (36.96) | 0.953 |
Met | 52 (57.78) | 80 (66.67) | 28 (63.64) | 29 (63.04) | |||
Tumor stage (n, %) | T1-T2 | 23 (25.56) | 40 (33.33) | 0.224 | 10 (22.73) | 7 (15.22) | 0.363 |
T3-T4 | 67 (74.44) | 80 (66.67) | 34 (77.27) | 39 (84.78) | |||
Age (years) | 63.57 ± 11.23 | 64.66 ± 9.89 | 0.456 | 64.50 ± 9.36 | 63.78 ± 10.17 | 0.729 | |
CEA (ng/mL) | 6.41 ± 8.46 | 12.92 ± 51.98 | 0.241 | 17.33 ± 52.44 | 8.13 ± 11.69 | 0.249 | |
Tumor size (cm3) | 19.79 ± 24.61 | 16.00 ± 15.70 | 0.175 | 22.86 ± 30.02 | 20.45 ± 35.23 | 0.728 | |
Dis (cm) | 8.27 ± 3.91 | 7.83 ± 3.67 | 0.397 | 7.63 ± 3.80 | 8.31 ± 3.52 | 0.382 | |